Indivior Reports Third-Quarter 2026 Revenue of $356 Million
Revenue rose 13.4% from $314 million a year earlier. Net income increased to $137 million from $42 million, and diluted EPS rose to $1.12 from $0.33.
Indivior Pharmaceuticals reported third-quarter 2026 net revenue of $356 million, up 13.4% from $314 million a year earlier. Net income increased to $137 million from $42 million, while diluted EPS rose to $1.12 from $0.33.Financial Highlights¹ Reported as “Net revenue”. ² Reported as “Net income”…